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Abstract
It is well-known that individuals with increased iron levels are more prone to thrombotic diseases, mainly due to the
presence of unliganded iron, and thereby the increased production of hydroxyl radicals. It is also known that erythrocytes
(RBCs) may play an important role during thrombotic events. Therefore the purpose of the current study was to assess
whether RBCs had an altered morphology in individuals with hereditary hemochromatosis (HH), as well as some who
displayed hyperferritinemia (HF). Using scanning electron microscopy, we also assessed means by which the RBC and fibrin
morphology might be normalized. An important objective was to test the hypothesis that the altered RBC morphology was
due to the presence of excess unliganded iron by removing it through chelation. Very striking differences were observed, in
that the erythrocytes from HH and HF individuals were distorted and had a much greater axial ratio compared to that
accompanying the discoid appearance seen in the normal samples. The response to thrombin, and the appearance of a
platelet-rich plasma smear, were also markedly different. These differences could largely be reversed by the iron chelator
desferal and to some degree by the iron chelator clioquinol, or by the free radical trapping agents salicylate or selenite (that
may themselves also be iron chelators). These findings are consistent with the view that the aberrant morphology of the HH
and HF erythrocytes is caused, at least in part, by unliganded (‘free’) iron, whether derived directly via raised ferritin levels or
otherwise, and that lowering it or affecting the consequences of its action may be of therapeutic benefit. The findings also
bear on the question of the extent to which accepting blood donations from HH individuals may be desirable or otherwise.
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Introduction
Iron overload is associated with many pathological conditions,
including liver and heart disease, neurodegenerative disorders,
diabetes, hormonal abnormalities immune system abnormalities,
heart failure, and in particular in the more classical conditions
recognised as ‘iron overload’ diseases such as hemochromatosis
(e.g. [1–14]). Moderate iron loading is also known to accelerate
thrombus formation after arterial injury, to increase vascular
oxidative stress, and to impair vasoreactivity [5,15–17]. Further-
more, iron-induced vascular dysfunction may contribute to the
increased incidence of ischemic cardiovascular events that have
been associated with chronic iron overload [15,18–20]. Poorly
liganded iron is the main culprit, and plays a fundamental role in
the development of pathology [1,2], while copper dysregulation
may also be of significance [21].
In 1976, Simon and co-workers first noted that idiopathic
hemochromatosis is a genetic disease and suggested that the
gene(s) responsible for the disease may be linked to the
histocompatibility genes [22]. The relevant (HFE) gene discovery
was only reported in 1996 [23]. HH is now probably the most
well-known genetic iron overload disease [24–26]. The most
common types of HH are caused by a C282Y or H63D mutation
in the protein encoded by the HFE gene [27–38]; HH individuals
may also be C282Y/H63D or present as a variety of heterozy-
gotes, where they have one copy of each of the mutation and a
wild type copy [39,40]. These types of HH are called type 1
(classical HFE gene mutations, resulting in a cysteine-to-tyrosine
substitution at amino acid 282 - C282Y) or a histidine-to-aspartate
substitution at amino acid 63 - H63D [41]. However, there are
also non-HFE haemochromatoses, which include all hemochro-
matosis disorders that are unrelated to the typical HFE mutations
[42]. Mutations in different genes are responsible for the distinct
types of non-classical HFE hemochromatosis, including hepcidin
[43,44] and hemojuvelin (type 2 or juvenile hemochromatosis -
PLOS ONE | www.plosone.org 1 January 2014 | Volume 9 | Issue 1 | e85271resulting from mutations in iron regulatory protein, hemojuvelin –
HJV gene [45]), transferrin receptor 2 (type 3 hemochromatosis -
TFR2 gene [46,47]; and mutations in the iron exporter,
ferroportin 1 [48] (mutated in type 4, the atypical dominant form
of primary iron overload - SLC40A1 gene) [41,42,49].
In the current work, HH will refer to type 1 or classical
hemochromatosis, based on mutations in the HFE gene, as
confirmed herein by genotyping. The genes linked to HH cause
disruption of the mechanisms that regulate iron absorption,
leading to progressive increase of total body iron and organ
damage [42]. Therefore, HH is indicative of disruption of the HFE
gene product, as well as commonly (but not inevitably) a persistent
elevation of serum ferritin concentration [42,50]. Here we also
classify hyperferritinemia (HF) as occurring in individuals with
high serum ferritin levels (higher than 200 ng/mL
21 for females
and 300 ng/mL
21 for males) but not with the genetic mutation in
the HFE gene (these individuals were tested for all combinations of
the C282Y, H63D as well as S65C mutations, and found to be
wild type for these mutations). Serum ferritin levels remain an
important indication of iron overload in HH, and therefore is an
important diagnostic tool [41,51–53].
One of the main medical complications of hemochromatosis is
that uncontrolled iron leads to tissue damage derived from free
radical toxicity caused by the excessive levels of this metal [41,54–
57]. Previously, we have shown that when ferric iron is added to
whole blood taken from healthy individuals, the red blood cell
morphology is changed [58]. We have also seen that in diabetes
(where iron overload is sometimes also present - and these diseases
may be mutually causative [2,13,51,59–65]) RBCs are elongated
and twist around fibrin fibers [66]. The possible hydroxyl radical
formation, due to excess iron, or the excess iron itself, may
therefore, as can many drugs [67], change red blood cell and fibrin
fiber ultrastructure, as both RBCs and coagulation factors are
exposed to particularly high serum ferritin and/or iron that may
ultimately cause hydroxyl radicals to be produced in the serum.
In view of the above, we here investigate the RBC morphology
in blood from individuals with hemochromatosis, in the presence
or absence of thrombin, and also study fibrin fiber morphology.
To make the logic behind this study and its mechanistic
hypotheses the clearer, and following the precepts of Wong [68],
we now include a descriptive Figure 1 that sets out the structure of
the manuscript.
We also add iron-chelating and other compounds to determine
any stabilizing effect of these substances on both RBC ultrastruc-
ture and fibrin fiber morphology. We observe remarkable
difference in morphology between RBCs from hemochromatosis
and hyperferritinemic individuals relative to those from normal
controls, with certain kinds of iron chelator and hydroxyl radical
scavenger being able to return the aberrant morphology to near-
normal states. It is unknown as to whether this aberrant
morphology of itself contributes to disease pathology (in the way
that aberrant morphology is well known to do in the case of sickle
cell disease [69]), but the present findings would possibly open the
debate about the desirability of using blood donations from HH
individuals.
Materials and Methods
Ethical approval was granted at the University of Pretoria
(HUMAN ETHICS COMMITTEE: FACULTY OF HEALTH
SCIENCES) under the name E Pretorius. Healthy individuals:
written informed consent was obtained from all healthy individuals
used as controls. Hemochromatosis and wild type blood:
throwaway blood was obtained from a routine genetics laboratory
(AMPATH National Reference Laboratory) after blood was sent
for genetic testing. The blood tubes came from all over South
Africa from various Pathology depots, to a central Genetic
laboratory for genetic testing. The Genetics laboratory obtained
written consent in order to perform the genetic testing. As for the
erythrocyte analysis, no additional written consent was obtained,
as the individuals were not identified for the academic part of the
study. No contact details were available where patients could be
identified or contacted. Given this, the institutional review board
waived the need for written informed consent, for the academic
part of the study, from these participants.
Twenty non-smoking healthy individuals with no chronic
diseases and who do not use any medication, served as control
subjects. SEM pictures of their RBC were compared to those in
our SEM database (of thousands of micrographs) and found to be
comparable. Hemochromatosis individuals were previously geno-
typed as H63D/H63D; C282Y/C282Y; H63D/wild type and
C282Y/wild type and all where Cacausians. Furthermore, wild
types, with high serum ferritin levels were included in the current
study. Blood samples from Hemochromatosis individuals were
obtained from the South African National Blood Services. Serum
ferritin levels, free iron, transferrin and % saturation were also
measured. Currently a hemochromatosis SEM database of RBC
and fibrin fiber networks with and without thrombin is being
created. Ethical clearance was obtained for the study from the
University of Pretoria Human Ethics Committee: E Pretorius as
principal investigator (Ethics Approval Number 151/2006).
Genomic DNA from 5 ml human blood samples collected in
EDTA tubes was isolated using the MagneSil KF Genomic System
on the KingFisher ML instrument. A multiplex PCR to determine
the HFE C282Y and H63D mutations was performed using
fluorescent hybridization probes specifically adapted for PCR in
glass capillaries using the ROCHE 480 Light Cycler. A Melting
Curve program is used to genotype the human genomic DNA
samples. The resulting melting peaks allow discrimination between
the homozygous (wild type or mutant) as well as the heterozygous
genotype [70].
Whole blood samples from healthy individuals and individuals
with hemochromatosis were obtained in Ethylenediaminetetra-
acetic acid (EDTA) blood tubes [71]. To prepare whole blood
smears, 10 ml aliquots were directly placed on a glass cover slip
with and without the addition of 5 ml human thrombin (20 U/
mL). Platelet rich plasma (PRP) (10 ml aliquots) was also prepared
and mixed with 5 ml thrombin [8].
Desferal, salicylate, sodium selenite and clioquinol were
prepared as stock solutions at 10 mM concentrations (stock
solution 1) as well as a lower stock solution of 0.5 mM (stock
solution 2) for each of the compounds used. The final concentra-
tions after dilution and after adding stock solution 1 and 2, are
shown in Table 1.
Whole blood smears for light microscopy were prepared by
making a blood smear with 10 ml of whole blood on to a
microscope slide. The smear was allowed to dry on a hotplate for 5
minutes or until completely dry followed by fixing in 100%
methanol and staining with methylene blue for (4 minutes) and
eosin (30 seconds). Smears were viewed with a Nikon Optiphod
transmitted light microscope (Nikon Instech Co., Kanagawa,
Japan).
Axial ratios of RBCs from healthy individuals, from those with
HH mutations, and from various wild types with or without
chelating and hydroxyl trapping compounds (0.5 mM concentra-
tion), were captured using ImageJ (ImageJ is a public domain,
Java-based image processing program developed at the National
Institutes of Health: http://rsbweb.nih.gov/ij/). Axial ratios were
Erythrocytes and Fibrin in Iron Overload
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overall as the numerator and the largest diameter at 90u to the line
used to provide the numerator as the denominator. Box plots and
other statistics were calculated using MS-Excel, together with the
add-in template downloadable from http://www.vertex42.com/.
In descriptive statistics, a box plot is a convenient way of
graphically depicting groups of numerical data through their
quartiles [72]. P values were calculated from the means, the
numbers of objects measured in each class and the standard
deviations using the Excel add-in available via http://www.
talkstats.com/attachment.
Figure 1. An overview figure summarizing the contents of this manuscript. 1) Literature suggests that there is a rationale for looking at the
vascular system and particularly blood; 2) we propose a mechanistic hypothesis; 3) our sample was chosen to be a random group of hereditary
hemochromatosis and hyperferritinemia individuals, along with controls; 4) our tissue of choice was blood where we looked at the morphology of
erythrocytes with and without the addition of chelators and iron trapping compounds; 5) our choice of methods involved microscopy techniques as
well as statistical analysis of iron levels.
doi:10.1371/journal.pone.0085271.g001
Table 1. Volumes of platelet rich plasms (PRP), whole blood (WB) and thrombin (T) versus concentration and volume of iron-
chelating and related compound.
Volumes and concentrations Final compound concentration
10 mlP R P +5 mlT +5 ml of 10 mM (stock solution 1) compound. 2.5 mM
10 mlW B +5 mlT +5 ml of 10 mM (stock solution 1) compound. 2.5 mM
10 mlP R P +5 mlT +5 ml of 0.5 mM (stock solution 2) compound. 0.125 mM
10 mlW B +5 mlT +5 ml of 0.5 mM (stock solution 2) compound. 0.125 mM
10 mlW B +5 ml of 10 mM (stock solution 1) compound. 3.33 mM
10 mlW B +5 ml of 0.5 mM (stock solution 2) compound. 0.167 mM
doi:10.1371/journal.pone.0085271.t001
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http://www.graphpad.com/quickcalcs/ttest1.cfm?Format=SD.
The cover slips with prepared smears were incubated at room
temperature for 5 minutes and were then immersed in 0.075 M
sodium phosphate buffer (pH 7.4) and finally placed on a shaker
for 2 minutes. Smears were fixed in 2.5% gluteraldehyde/
formaldehyde (1:1) in PBS solution with a pH of 7.4 for 30
minutes, followed by rinsing 36 in phosphate buffer for five
minutes before being fixed for 30 minutes with 1% osmium
tetroxide (OsO4). The samples were again rinsed 36with PBS for
five minutes and were dehydrated serially in 30%, 50%, 70%,
90% and three times with 100% ethanol. The material was critical
point dried, mounted and coated with carbon. A Zeiss ULTRA
plus FEG-SEM with InLens capabilities were used to study the
surface morphology of platelets and micrographs were taken 1 kV.
This instrument is located in the Microscopy and Microanalysis
Unit of the University of Pretoria, Pretoria, South Africa.
Results
We choose to provide the data in the form of micrographs, that
illustrate the typical morphologies we observe, along with
statistical analyses of many measurements to provide the necessary
robustness or powering [72]. All individuals were tested for the
HH mutation. They were sent for testing by their medical
practitioners due to the fact that the all had symptoms of iron
overload including possible organ damage. Most of the HH
individuals have increased SF levels, while all HF individuals (by
definition) have increased SF levels. Increased serum iron was
taken as above 30 mmol.L
21; transferrin levels that were below
2.1 g/L
21 were taken as atypical and % saturation above 45%
were taken as atypical. Table 2 shows the reference serum ferritin
values typically used to determine the presence of iron overload;
while Table 3 shows normal ranges for serum iron, transferrin and
% transferrin saturation.
Tables 4 and 5 show the profiles of our HH and HF patients,
while Figures 2 and 3 show box plots and statistics for serum
ferritins (SFs) and serum irons (SIs) for controls, HH and HF
individuals. Statistical analyses (data shown at the bottom of
Figures 2 and 3) confirm that both the HH and HF groups have
increased SF levels, compared to those of healthy individuals (p-
value,0.05). We could not find any correlation between serum
iron, transferrin and % saturation and the presence of the HH
mutation (an illustration of the serum iron data is given in Table 5).
However, many patients with HF also had increased SF levels and
in some cases the 3 other values were also increased (see Table 5).
From the data in Table 5, it therefore seems as if SF levels are the
iron-related value that most effectively imply or reflect the
presence of the HH mutation.
Figure 4 shows a box plot of axial ratios, with statistics for
controls and HH individuals; and also HH RBCs with and without
chelating and hydroxyl trapping agents. Figure 5 similarly shows a
box plot of axial ratios for HF individuals, and also HF RBCs with
and without chelating and hydroxyl trapping agents.
Axial ratios of RBCs in healthy control individuals are close to
1, which is indicative of their well-known, common discoid shape.
Both the HH and wild type individuals show a significantly
elongated shape as seen in their axial ratios, and these also have a
much greater variance. However, when the iron-chelating
compounds are added, RBCs appear to revert to the typical
discoid shape. Although the serum ferritin concentrations in HH
individuals are not significantly different from those of the
controls, they do exhibit a very much greater variance, while the
concentrations in those with hyperferritinaemia are of course (by
definition) substantially greater (Figure 2). By contrast, there were
no significant differences in serum iron (transferrin-bound iron)
between the controls, HH or HF samples (Figure 3).
P values assess the probability of the null hypothesis being true
(i.e. that all objects are from the same population and thus not
‘different’ from each other) [72]. For controls (17 individuals), HH
(13 individuals) and HF (4 individuals), axial ratios of 20 cells per
individual were measured (controls: n=340; HH: n=260; HF:
n=80). For each of these HH and HF individuals, compounds
were added to WB and axial ratios of 20 cells per added
compound were again measured. The mean values for the axial
ratios for HH cells differed highly significantly from those of
control cells (p,0.0001), and also from those treated with desferal,
salicylate, selenite and clioquinol (P,0.0001 in every case). As with
Table 2. A series of analyses indicating that serum ferritin levels are taken as an indicator of Hemochromatosis, hyperferritinemia,
and in healthy individuals.
Healthy individuals
Males: 25 –300 mg/L
21; Females: 25 – 200 mg/L
21[73]
Levels of serum ferritin taken as indication for Hemochromatosis
Serum ferritin above approximately females 200 mg/L
21 and males 300 mg/L
21. [41,53,74–79].
88% of males with homozygous C282Y mutation individuals serum ferritin levels were greater than 300 mg/L
21 and in females 57% had levels greater than 200 mg/
L
21[77].
Severe overload - serum ferritin levels more than 1000 mg/L
21[55,80].
Severe overload - serum ferritin levels more than $239 mg/L
21 [51].
Ideal maintenance for Hemochromatosis: 25 – 50 mg/L
21 [73,75].
doi:10.1371/journal.pone.0085271.t002
Table 3. Normal values for serum iron, transferrin and %
transferrin saturation.
Normal values for serum iron
11.6 – 31.4 mmol/L
21 [81]
Normal values for transferrin
2.2 – 3.7 g/L
21 [81]
Normal values for % transferrin saturation
20–50% [81]
up to 45% [82–84]
doi:10.1371/journal.pone.0085271.t003
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significantly from those of controls (P,0.0001) and from those
treated with desferal, salicylate, selenite or clioquinol (P,0.0001 in
every case).
Figures 6, 7, 8, 9, 10, 11 show SEM and LM micrographs (see
the illustration in Figures 6D and 7G: RBC with measurement
lines for axial ratios, indicated by arrows in each micrograph).
Figure 6A–C shows SEM micrographs of typical healthy RBC,
whole blood (WB) with thrombin, as well as PRP with added
thrombin. These individuals do not have increased SF, and do not
smoke nor use any chronic medication. As expected, RBCs of such
healthy individuals show a typical discoid shape (Figure 6A). When
thrombin is added to WB, the RBCs keep their typical discoid
shape; however, fibrin fibers form over and around the RBCs
(Figure 6B). When PRP is mixed with thrombin, a typical fiber net
is formed (Figure 6C). Figure 6D shows a light microscopy smear
of a healthy individual. We have previously shown that the
exposure of whole blood to physiological levels of iron (0.03 mM
FeCl3) causes RBC shape change [85]. This can be seen in
Figure 3E. Figure 3F also shows how ‘healthy’ fibrin changes in
the presence of iron.
By contrast, Figure 7A–D show SEM micrograph smears from
blood taken from HH and HF individuals. HH RBCs typically
have a substantially changed shape, where they become elongated,
with pointed extensions (Figure 7A). Interestingly, in HH where
SF is within normal ranges, RBCs still have an elongated shape
(Figure 7B). This was noted in all individuals with the mutation but
where SF levels are within the normal ranges. A changed RBC
and fibrin network morphology was also noted for HF individuals
with SF levels higher than 200 mg/L
21 (females) and 300 mg/L
21
(males) (Figure 7C). Thus either HH or HF alone is sufficient to
cause the aberrant morphology. Figure 7D shows whole blood
from a female HH individual (SF=219 mg/L
21) with added
thrombin, where the RBCs are entrapped and deformed in the
fibrin mesh. Figure 7E shows PRP and thrombin from an HH
individual (SF=1166 mg/L
21), where the typical fibrin fibers
coagulate to form a tighter meshed network. It is known that
iron ions may inhibit thrombin activity ([86]). Here this changed
fibrin morphology may in part be the result of this inhibition.
The same ultrastructure is seen in HF individuals (Figure 7F –
SF=1230 mg/L
21).
Figure 7G shows a light microscopy micrograph of a typical HH
individual with SF in the normal range (179 mg/L
21); and
Figure 7H, that of an HF individual (SF=506 mg/L
21). The
shape changes seen in some of the RBCs are typical of a
representative light microscopy view of the whole smear.
Interestingly, all HH individuals whose SF levels are within
normal ranges (Table 4, low SF levels shown in italics) still have a
changed RBC shape.
We also exposed PRP and WB from HH and HF (with and
without thrombin) individuals to 2.5 mM and 3.33 mM and
desferal (Figure 8A–C), sodium salicylate (Figure 9A–C), sodium
selenite (Figure 10A–C) or clioquinol (Figure 11A–C) (Table 1). A
second round of experiments (Figures 8–11 D–F) was done at 20-
fold lower concentration of the compounds were added (Table 1).
To assess the extent of the changes, RBC light microscopy was
included for low concentrations of all compounds (Figures 8–11
G). Desferal is the classical iron chelator; however, it has poor
gastrointestinal absorption and therefore has to be administered
intravenously or subcutaneously [87–89]. Sodium salicylate is a
known trap for free radicals [90,91], and is an active metabolite of
aspirin [92] and we previously showed that it has a protective
Figure 2. A box plot drawn from serum ferritin (SF) values for healthy individuals, HH and HF individuals.
doi:10.1371/journal.pone.0085271.g002
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selenite is an assimilable form of an essential trace element (Se)
with antioxidant, immunological, and anti-inflammatory proper-
ties [93]. This said, we note that we cannot absolutely exclude that
salicylate and selenite also have some iron-chelating activities,
since catechol (structurally related to salicylate) does [94], and
salicylate is part of the siderophore enterobactin [95], while the
solubility product of ferric selenite is rather low [96,97]. Clioquinol
has the ability to chelate and redistribute iron [98] and is emerging
as a potential therapy for some diseases, such as Alzheimer’s
disease [99] and cancer [100]. The ‘high’ concentrations of all the
compounds stabilized the RBC and fibrin morphology. Although
the lower concentrations also showed a stabilizing effect, it was not
as profound as that seen with the high concentrations. Neverthe-
less, here we saw that both concentrations of the compounds
stabilized ultrastructure in both HH (low and high SF levels) and
HF individuals.
Discussion
Excess iron levels are associated with Alzheimer’s disease,
Parkinson’s disease, Huntington’s disease, Friedreich’s ataxia and
other neurological disorders, cancer, Fanconi anemia, stroke,
heart disease, diabetes and ageing [1,2,5,18,19,54,101–110]. One
of the hereditary diseases necessarily associated with iron overload
is hemochromatosis, where iron overload causes oxidative stress
that ultimately damages organs. An unanswered question remains
as to what extent, and by what mechanisms, hereditary (or other)
iron overload conditions may contribute to the clinical manifes-
tation of the conditions listed above.
We have recently shown that high added iron may impact on
the coagulation profile and RBC ultrastructure [66,111]. Previ-
ously, we have documented that ferric ions can activate non-
enzymatic blood coagulation, resulting in the formation of fibrin-
like dense matted deposits (DMDs) demonstrable by SEM [112].
Azizova and co-workers also noted that iron causes oxidative
modification of thrombin [86]. RBCs also change morphology
under elevated iron levels [96]. Further, it is also known that
hemoglobin (Hb) content in HH is raised [113,114]; however, the
ultrastructure of fibrin fibers and RBCs in blood in HH seem not
to have been investigated previously. Currently, we know that iron
may change fibrin fiber shape and packaging, when added at
physiological levels [8,66]. We have also shown [8] that in
diabetes, if elevated iron levels are present, changes in fibrin fibers
as well as RBC structure occur. This was ascribed to another,
pathological pathway of fibrin formation initiated by free iron
(initially as Fe (III)), leading to the formation of highly reactive
oxygen species such as the hydroxyl radical, that can oxidise and
insolubilize proteins, a process that might be inhibited by iron-
chelating compounds [8]. The final product of such a pathway is a
fibrin-like material, termed dense matted deposits (DMDs) that are
remarkably resistant to proteolytic degradation. We developed a
laboratory platelet rich plasma (PRP) as well as a functional
fibrinogen model where we used scanning electron microscopy
(SEM) [58] to show that iron-chelating agents can be effective
inhibitors of DMD formation [8]. Of a small range tested, the
most active inhibitors of DMD formation proved to be desferal,
Figure 3. A box plot drawn from serum iron (SI) values for healthy individuals, HH and HF individuals.
doi:10.1371/journal.pone.0085271.g003
Erythrocytes and Fibrin in Iron Overload
PLOS ONE | www.plosone.org 6 January 2014 | Volume 9 | Issue 1 | e85271clioquinol and curcumin, whereas epigallocatechin gallate and
deferiprone were less effective. In the present work, we also
investigated the protective effect of the direct free radical
scavenger, sodium salicylate, as well as sodium selenite, by
pretreating iron-exposed PRP and purified fibrinogen with these
candidate molecules [7], though as noted above we cannot entirely
exclude that they can chelate iron too. We suggested that the
hydroxyl radicals produced by iron exposure, are neutralized e.g.
by their conversion to molecular oxygen and water, thus inhibiting
the formation of dense matted fibrin deposits in human blood and
our laboratory fibrinogen model [7]. We note too the role of iron
in the production of other dense cellular deposits such as lipofuscin
(e.g. [115–118]), and we should also recognise that the ferric iron,
as a trivalent cation, necessarily has profound electrostatic effects,
simply from the Debye-Hu ¨ckel theory. Finally, we note that that
patients do have (excess) unliganded iron, that we also measure the
variations in ferritin levels between individuals, and ferritin, even
in serum, contains iron (see e.g. [119–121].
Perhaps surprisingly, very little is known about the RBC
ultrastructure and fibrin network packaging in hemochromatosis
individuals. In 1997 Akoev and co-workers showed that RBC
membranes in hemochromatosis display an aggregation and
enlargement of intra-membrane particles in comparison with
structures seen in membranes from healthy donors [122]. In the
present work, we demonstrate that the gross morphology of RBCs
from HH individuals, as well as their fibrin fiber ultrastructure, is
Table 4. Profiles of Hereditary Hemochromatosis and genetically wild type individuals with high serum ferritin (SF) levels used in
this study (rows in italics show individuals with SF values that are within normal ranges: females #200 ng/mL
21; males #300 ng/
mL
21).
Gene Serum ferritin (ng/mL
21) Age Gender Representative Figure
H63D/H63D 1613 52 M
C282Y/C282Y 15 22 M 3B
C282Y/C282Y 389 44 M
C282Y/C282Y 1113 46 M
C282Y/C282Y 508 37 F 3A
C282Y/H63D 374 72 F
C282Y/H63D 5 24 F
C282Y/H63D 69 11 F
C282Y/H63D 27 13 M
C282Y/H63D 1019 58 M
C282Y/H63D 1166 59 F 3E
C282Y/wild type 1344 63 M
C282Y/wild type 506 53 M
C282Y/wild type 79 12 M
C282Y/wild type 68 64 M 4G, 5G, 6G, 7G
C282Y/wild type 219 54 F 3D
H63D/wild type 625 52 M 4,5,6,7 A–F
H63D/wild type 468 48 M
H63D/wild type 179 19 M 3G
H63D/wild type 594 46 M
H63D/wild type 242 50 F
H63D/wild type 634 44 F 4A, B, C
AVERAGE 511.64 43
WILD TYPE (Genetically tested due to a history of familial HH and high SF)
Wild type 242 57 F
Wild type 841 55 F
Wild type 506 53 M 3H
Wild type 303 51 M 3C
Wild type 1230 66 M 3F
Wild type 790 58 F
Wild type 479 86 F
Wild type 1736 62 M
Wild type 860 41 M
Wild type 453 57 M
AVERAGE 512 59
doi:10.1371/journal.pone.0085271.t004
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with a much greater axial ratio compared to the appearance seen
in the normal discoid samples. Previously, we have also shown
with atomic force microscopy (AFM), that in diabetes the RBC
membrane architecture is changed [123]. The RBC membrane
consists of an overlaying asymmetric phospholipid bilayer
membrane [124], supported by an underlying spectrin-actin
cytoskeletal complex, which is interconnected by junctional
complexes, resulting in a simple hexagonal geometric matrix.
The associations between spectrin and actin with the junctional
and ankyrin complexes are of fundamental importance for
allowing erythrocytes to maintain their shape [125]. The plasma
membrane is anchored to the spectrin network mainly by the
protein ankyrin and the trans-membrane proteins band 3 (anion











C282Y/H63D 7 F 24 21.3 2.6 33
C282Y/H63D 1218 M 54 32.4 2 65
C282Y/H63D 9 M 64 5.8 3.5 7
C282Y/wild type 32.41 F 12 17.2 3.1 22
C282Y/wild type 313.8 M 12 37.3 2.1 71
C282Y/wild type 118 F 57 22.6 2.2 41
C282Y/wild type 113.7 F 39 25.8 2 52
C282Y/wild type 197 M 20 48.2 2.2 88
C282Y/wild type 807 M 48 22.8 2.7 34
C282Y/C282Y 389.7 M 44 21.5 2.1 41
C282Y/C282Y 501 M 26 40.3 2.1 77
H63D/H63D 83 F 43 10.8 2.1 21
H63D/wild type 634.1 F 44 29.2 3.4 34
H63D/wild type 242 F 50 9.7 2 19
H63D/wild type 159 M 63 13.3 3.4 16
H63D/wild type 6 F 44 13.2 2.8 19
H63D/wild type 594 M 46 34.8 3.4 41
H63D/wild type 469 M 39 15.4 2.4 25
H63D/wild type 483 M 56 40.1 2.7 59
H63D/wild type 1500 M 47 30.1 1.1 95
H63D/wild type 35 F 15 34.7 2.2 63
H63D/wild type 126 F 41 21.3 2.5 34
H63D/wild type 736 M 61 37.4 2.5 60
AVERAGES 381.46 42 25.4 2.5 44
Wild type 303 M 51 11.7 3.1 15
Wild type 790 F 58 28.8 2.9 40
Wild type 860 M 41 22.1 2.7 33
Wild type 453 M 57 23.3 2 47
Wild type 568 M 48 13.1 2 26
Wild type 527 M 51 24.7 2.2 45
Wild type 269 M 62 38.6 2.1 74
Wild type 1386 M 38 29.9 2.6 46
Wild type 1441 M 39 39.6 2.6 61
Wild type 259 F 63 9.8 2.7 15
Wild type 432 F 53 7.5 1.8 17
Wild type 562 M 44 18.9 2.6 29
Wild type 455 M 56 36.4 3.1 47
Wild type 1434 M 63 36.7 2.3 64
AVERAGES 695.64 51.71 24.4 2.5 40
HH and wild type individuals with serum ferritin (normal values: females #200 ng/mL
21; males #300 ng/mL
21) gender, age, serum iron (normal values: 11.6 –
31.4 mmol/L
21), transferrin (normal values: 2.2 – 3.7 g/L
21) and % saturation levels (normal values: 20 – 50%). Bold values indicate where levels do not fall into normal
value.
doi:10.1371/journal.pone.0085271.t005
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[126–128] and is substantially responsible for controlling the
rheological behavior and for withstanding the physical forces
associated with circulatory transport.
We reported that in diabetes a decreased surface roughness is
present, and that this is indicative of superficial protein structure
rearrangement [123]. Given the effects of non-membrane-
permeant chelators on the ability to reverse the morphological
changes observed in the current study, we suggest that the change
in RBC ultrastructure is driven by RBC membrane-induced
architectural changes. We therefore agree with Akoev and
coworkers that membrane architecture is changed in HH. This
view is also consistent with the well-known ability of amphipathic
cationic and anionic drugs to affect the membrane architecture of
RBCs [67,129–132].
Figure 4. A box plot of axial ratios of 20 cells from 17 healthy individuals (n=340) versus axial ratios of 20 cells from 13 HH
individuals (n=260) with and without chelating and other compounds (n=260 per compound). Micrographs were taken at 100x
magnification with a Nikon Optiphod transmitted light microscope (Nikon Instech Co., Kanagawa, Japan).
doi:10.1371/journal.pone.0085271.g004
Figure 5. A box plot of axial ratios of 20 cells from 17 healthy individuals versus 20 cells from 4 HF individuals (n=80) with and
without chelating and other compounds (n=80 per compound). Micrographs were taken at 1006magnification with a Nikon Optiphod
transmitted light microscope (Nikon Instech Co., Kanagawa, Japan).
doi:10.1371/journal.pone.0085271.g005
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saturation levels), RBCs are typically discoid-shaped, even
following the addition of thrombin (Figure 6A and B). The box
plot analyses also reflect this (Figure 4 and 5). When the
coagulation pathways are activated, fibrin fibers are generated
(in the presence of thrombin), forming a clot. This clot has RBCs
trapped in the network. This was also seen in our laboratory
investigation (Figure 6B). In HH, as well as in HF individuals, the
RBCs are highly entwined in the fibrin mesh, which might
ultimately result in a tighter clot (only HH individual shown -
Figure 7D).
Here we also show the effects of high and lower physiological
level exposure of desferal, salicylate, sodium selenite or clioquinol.
The higher additive concentrations (Figure 8–11 A–C) show a
definite RBC and fibrin network stabilization as noted with the
SEM data. Desferal stabilizes the RBC ultrastructure with and
without thrombin, and fibrin fibers also appear more like those of
a healthy individual (Figure 8). With the high desferal concentra-
tion, RBCs return to the typical, normal discoid-shaped, and with
added thrombin, they regain their discoid shape (Figure 8A and
B). The lower desferal concentration does not have such a
profound stabilizing effect as the higher concentration, as most of
the RBCs appear slightly elliptical rather than discoid. This is also
seen in the light microscopy micrograph (Figure 8G). PRP with
added thrombin, show more individual fibers between thicker
homogenous fibrin. Therefore, the typical net does not completely
form (Figure 8F) in the manner seen with the higher desferal
concentration. These results are seen for both HH and HF
individuals, suggesting that the reasons for the changed ultra-
structure is primarily due to the high SF levels.
In whole blood smears without thrombin, but with added
sodium salicylate, RBCs do not have the pointed extensions
(Figure 9A–C). However, with added thrombin, most of the RBCs
seem to be folded around the fibrin fibers, changing the typical
discoid shape (Figure 9B). Fibrin fibers were comparable to those
of healthy individuals (Figure 9C). Lower concentrations of the
additives did stabilize the RBC as well as fibrin fiber morphology
(Figure 9D – F). Light microscopy of whole blood with these lower
Figure 6. RBCs and fibrin networks from healthy individuals
with SF levels within normal ranges. A) RBC B) RBC with added
thrombin; C) Platelet rich plasma smear with added thrombin. D)
Typical light microscopy smear from a healthy individual. The cell
arrowed illustrates the means by which we determined the axial ratios.
E) Healthy RBC exposed to physiological levels of iron. F) Healthy PRP
exposed to physiological levels of iron showing matted masses (white
arrows). All SEM micrographs scales =1 mm; Light microscopy scale
=10mm.
doi:10.1371/journal.pone.0085271.g006
Figure 7. Micrographs from hereditary hemochromatosis (HH)
and hyperferritinemia (HF) individuals. A) RBC from HH individual
with high SF (508 mg/L
21) (C282Y/C282Y); B) RBC from HH individual
with low SF (15 mg/L
21) due to regular phlebotomy (C282Y/wild type)
C) Whole blood smear, showing elongated RBC from a HF individual
with high SF (303 mg/L
21); D) Whole blood smear, from HH with added
thrombin (C282Y/wild type) (219 mg/L
21); E) Platelet rich plasma smear
from HH with added thrombin (C282Y/H63D) (1166 mg/L
21); F) Platelet
rich plasma smear from HF individual with added thrombin (1230 mg/
L
21); G) Light microscopy smear from a H63D/wild type individual
(179 mg/L
21) - The cell arrowed illustrates the means by which we
determined the axial ratios; H) Light microscopy smear from a HF
individual with high iron levels (506 mg/L
21). All SEM micrographs
scales =1 mm. Light microscopy micrographs scales =10 mm.
doi:10.1371/journal.pone.0085271.g007
Figure 8. Micrographs of samples from patients with heredi-
tary hemochromatosis with added desferal. A) Whole blood with
added 10 mM desferal (H63D/wild type); B) Whole blood, with added
thrombin and 10 mM desferal (H63D/wild type); C) Platelet rich plasma
smear, with added thrombin and 10 mM desferal (H63D/wild type); D)
Whole blood with added 0.5 mM desferal (H63D/wild type); E) Whole
blood, with added thrombin and 0.5 mM desferal (H63D/wild type); F)
Platelet rich plasma smear, with added thrombin and 0.5 mM desferal
(H63D/wild type); G) Light microscopy of whole blood with 0.5mM
desferal (C282Y/wild type). All SEM micrographs scales =1 mm; light
microscopy micrograph scale =10 mm.
doi:10.1371/journal.pone.0085271.g008
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The same pattern was seen in the presence of sodium selenite
(Figure 10A–C), except that it seems as if the RBC kept their shape
better in the presence of the sodium selenite and thrombin.
Clioquinol showed anomalous results, where RBC with and
without thrombin kept their pointed appearance and the fibrin
fibers also coagulated into DMDs with very few individual fibers
visible.
The lower additive concentrations (Figure 8–11 D–F) for all
products, show a less prominent stabilizing effect when viewed
with SEM. However, light microscopy of samples in the presence
of the lower concentrations clearly show that most of the RBCs
have returned to the discoid shape. This was noted for HH as well
as wild type/wild type individuals with higher than the accepted
healthy serum iron levels (200 ng/mL
21 for females and 300 ng/
mL
21 for males).
Individuals with hemochromatosis – as an ‘iron overload
disease’ – are well known to have significantly more ‘iron’ in
their bodies than do normal controls, and this is considered to
contribute to the attendant gross pathologies of this syndrome.
Phlebotomy and iron chelation are thus two therapies in common
use [73,80,87]. Here we establish that accompaniments of this
excessive iron in hemochromatosis whole blood are changes in
both RBC morphology and in fibrin fibers, possibly due to
hydroxyl radical formation or to the presence of excess iron itself.
If hydroxyl radicals are involved, we suggest that they can cause
non-enzymatic changes to fibrin in the presence of thrombin and a
changed RBC ultrastructure, where the cells lose their discoid
shape and are easily deformed when fibrin and DMDs are
produced in the presence of thrombin. Ferric ions may also bind to
the outer surface of the RBC directly [58]. As expected, the
classical iron chelator, desferal, showed a stabilizing effect on both
Figure 9. Micrographs of samples from patients with heredi-
tary hemochromatosis with added sodium salicylate. A) Whole
blood with added 10 mM sodium salicylate (H63D/wild type); B) Whole
blood, with added thrombin and 10 mM sodium salicylate (H63D/wild
type); C) Platelet rich plasma smear, with added thrombin and 10 mM
sodium salicylate (H63D/wild type); D) Whole blood with added 0.5 mM
sodium salicylate (H63D/wild type); E) Whole blood, with added
thrombin and 0.5 mM sodium salicylate (H63D/wild type); F) Platelet
rich plasma smear, with added thrombin and 0.5 mM sodium salicylate;
G) Light microscopy of whole blood with 0.5 mM sodium salicylate
(C282Y/wild type). All SEM micrographs scales =1 mm; light microscopy
micrograph scale =10 mm.
doi:10.1371/journal.pone.0085271.g009
Figure 10. Micrographs of samples from patients with hered-
itary hemochromatosis with added sodium selenite; A) Whole
blood with added 10 mM sodium selenite (H63D/wild type); B)
Whole blood, with added thrombin and 10 mM sodium
selenite (H63D/wild type); C) Platelet rich plasma smear, with
added thrombin and 10 mM sodium selenite (H63D/wild type);
D) Whole blood with added 0.5 mM sodium selenite (H63D/
wild type); E) Whole blood, with added thrombin and 0.5 mM
sodium selenite (H63D/wild type); F) Platelet rich plasma
smear, with added thrombin and 0.5 mM sodium selenite
(H63D/wild type); G) Light microscopy of whole blood with
0.5 mM sodium selenite (C282Y/wild type). All SEM micrographs
scales =1 mm; light microscopy micrograph scale =10 mm.
doi:10.1371/journal.pone.0085271.g010
Figure 11. Micrographs of samples from patients with hered-
itary hemochromatosis with added clioquinol. A) Whole blood
with added 10 mM clioquinol (H63D/wild type); B) Whole blood, with
added thrombin and 10 mM clioquinol (H63D/wild type); C) Platelet
rich plasma smear, with added thrombin and 10 mM clioquinol (H63D/
wild type); D) Whole blood with added 0.5 mM clioquinol; E) Whole
blood, with added thrombin and 0.5 mM clioquinol (H63D/wild type);
F) Platelet rich plasma smear, with added thrombin and 0.5 mM
clioquinol (H63D/wild type); G) Light microscopy of whole blood with
0.5 mM clioquinol (C282Y/wild type). All SEM micrographs scales
=1mm; light microscopy micrograph scale =10 mm.
doi:10.1371/journal.pone.0085271.g011
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and redistribute iron [98,99,133–136]. However, in the current
work, it showed the least potential to stabilize RBCs and fibrin. By
contrast, salicylate and sodium selenite showed excellent stabilizing
properties. Previously we have shown that sodium selenite inhibits
fibrinogen polymerization, and suggested that this may occur by
oxidation of hydroxyl radicals and the concomitant reduction of
Se
4+ to Se
2+ [7]. Salicylate is also known to be a direct free radical
scavenger and recently it has been shown that it affords protection
against rotenone-induced oxidative stress and therefore has
neuroprotective potential against OH
N radical damage [92,137].
In the current study, sodium selenite and sodium salicylate
plausibly also inhibited the hydroxyl radicals produced by the
increased iron present in hemochromatosis, but as mentioned
above may well also have bound or chelated some of the free iron.
The current research has shown that iron causes structural
changes, but that selected additives cause a reverting of the
structure; this suggests that the damage seen is indeed reversible.
As discussed in the previous paragraphs, iron causes oxidative
stress in cells. However, in the current manuscript we did not look
at the specific markers that might cause oxidative damage, e.g. the
presence of ROS in the RBCs. Some of the effects might be purely
due to binding, e.g. via electrostatic effects. However, published
research suggests that in the presence of high iron levels, RBCs
and their precursors have more ROS than do their normal
counterparts [138]. Furthermore, it has also been shown that
chelators, including deferiprone, deferasirox and deferoxamine
reduce the oxidative status of thalassaemic RBCs [138]. Further
research, including the unravelling of the exact molecular
mechanisms behind the shape changes would provide important
insights into the treatment of iron overload diseases; however, tt is
outwith the scope of this paper.
There is also discussion [139,140] as to the utility or otherwise
of using HH individuals as blood donors [141]. The present
findings, indicating that the aberrant erythrocyte morphology is a
property of individual cells (and not an ensemble in the
thermodynamic sense [142]), suggest that care may need to be
taken in the use of blood from HH donors. The reversibility of the
aberrant morphologies of the RBC of HH donors under the
conditions normally used in blood banks should therefore be
checked.
Overall, we found remarkable changes in the morphology of
RBCs in individuals with HH and SF, and showed that to an
extent these can be reversed by chelators of unliganded iron and
molecules that are known to stop their sequelae in terms of
hydroxyl radical formation. An interesting observation is that even
if SF levels are within normal ranges for the HH individuals, they
still have a changed RBC and fibrin network ultrastructure. SF
levels are therefore not the only parameter that changes
ultrastructureAt all events, as illustrated by the independence of
HH and HF, the ability to cause a raising of serum ‘iron’ is a
systems property, reflecting the interplay between SF and all other
aspects of the iron metabolic network. In HH individuals and wild
type individuals where SF is high, a changed RBC shape is also
noted, and the axial ratios reflect this. We could not find a clear
correlation between the 3 other typical pathology laboratory
results requested by medical practitioners and the presence of the
HH mutation (Table 5).
This said, it seems as if increased serum ferritin levels in the HF
individuals do indeed cause (or accompany) changes in ultrastruc-
ture. This could be seen as consistent with the view that the
morphological changes are caused not only by the raised Hb levels
in such RBCs [113,114] but by unliganded iron itself. Whether
this aberrant morphology contributes to disease pathology is not
known, but an interesting parallel can be made with sickle cell
disease. Here it is definitely known that the altered RBC
morphology contributes to pathology as the deformed erythrocytes
struggle to pass through blood capillaries, often leading to stroke
[143–148]. Iron parameters are often raised in sickle cell disease
too, including as a result of transfusion treatment [149–155]. It
would thus be of interest to assess the effects of iron chelators on
sickle cell morphologies directly.
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